Treatment of Cushing's disease with adrenal blocking drugs and megavoltage therapy to the pituitary.
Eighteen patients with Cushing's disease were seen over a 40-month period and considered for treatment by pituitary irradiation and adrenal blocking drugs. Fourteen patients entered the study and each received megavoltage therapy to give a mean dose of 4600 rad to the pituitary over 31 days. Each patient was treated for one (two patients) or two (12 patients) years with one or both of the adrenocortical enzyme inhibitors, metyrapone or aminoglutethmide to suppress cortisol secretion. Doses were adjusted to maintain urinary free cortisol secretion below 300 nmol/24 h. One patient failed to complete the trial. Normal urinary free cortisol excretion and plasma cortisol concentration were maintained after treatment in eight of the remaining 13 patients after therapy. Only one patient required cortisol replacement and normal menstrual function was restored in five of the six women. The remaining five patients relapsed and four were subsequently treated by total adrenalectomy. It was noted that the patients who responded to treatment were substantially younger than the therapeutic failures. It is suggested that this treatment is most useful in the management of younger patients.
D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000328:Adult; D000367:Age Factors; D000368:Aged; D000616:Aminoglutethimide / Q000627:therapeutic use*; D003480:Cushing Syndrome / Q000378:metabolism / Q000628:therapy*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D008297:Male; D008797:Metyrapone / Q000627:therapeutic use*; D008875:Middle Aged; D010910:Pituitary Irradiation; D011882:Radiotherapy, High-Energy; D013997:Time Factors
D000616:Aminoglutethimide; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone; D008797:Metyrapone